Another study conducted by Liu et al. found antagonist of ADORA1 promotes tumor PD-L1 expression via the cAMP-CREB-ATF3 axis and improves immunotherapy efficacy by increasing CD8 positive T cell activity in lung cancer 36. Here, CD8A is linked to lung cancer.